NRF2 silencing or pharmacological inhibition by brusatol reduced the proliferation and migration of breast cancer (BC) cells, inhibited proliferation, activated apoptosis, sensitized BC cells to cisplatin in vitro, and slowed tumor cell growth in vivo [59]. Here, NFE2L2 is linked to neoplasm.